{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:05:42Z","timestamp":1787241942030,"version":"build-2736575974"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We sought to identify immunoglobin G autoantibodies predictive of early treatment response to methotrexate, the recommended first-line therapy for patients with newly diagnosed rheumatoid arthritis, and to the interleukin-6 receptor inhibitor biologic tocilizumab, initiated as the first disease-modifying anti-rheumatic drug.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>In baseline sera of a subset of patients with newly diagnosed rheumatoid arthritis in the U-Act-Early study, selected based on specific responder\/non-responder criteria using the Disease Activity Score assessing 28 joints (DAS28) within the first 20 weeks, we measured immunoglobin G antibody reactivity against 463 protein antigens and performed supervised cluster analysis to identify predictive autoantibodies for treatment response. The analysis subset comprised 56 patients in the methotrexate arm (22 responders, 34 non-responders) and 50 patients in the tocilizumab arm (34 responders, 16 non-responders). For comparison, these analyses were also performed in 50 age- and gender-matched healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Increased reactivity in responders versus non-responders was found in the methotrexate arm against two antigens\u2014DOT1-like histone lysine methyltransferase (p = 0.009) and tropomyosin (p = 0.003)\u2014and in the tocilizumab arm against one antigen\u2014neuro-oncological ventral antigen 2 (p = 0.039). Decreased reactivity was detected against two antigens in the methotrexate arm\u2014G\n                      <jats:sub>1<\/jats:sub>\n                      to S phase transition 2 (p = 0.023) and the zinc finger protein ZPR1 (p = 0.021). Reactivity against the identified antigens was not statistically significant in either treatment arm for patients with rheumatoid factor\u2013positive versus\u2013negative or anti-cyclic citrullinated test\u2013positive versus test\u2013negative rheumatoid arthritis (p \u2265 0.06).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Comprehensive profiling of baseline sera revealed several novel immunoglobin G autoantibodies associated with early treatment response to methotrexate and to tocilizumab in disease-modifying anti-rheumatic drug-naive patients with rheumatoid arthritis. These findings could eventually yield clinically relevant predictive markers, if corroborated in different patient cohorts, and may facilitate future benefit in personalised healthcare.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0241189","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T14:32:02Z","timestamp":1607610722000},"page":"e0241189","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8896-6341","authenticated-orcid":true,"given":"Xavier M.","family":"Teitsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Devenport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W. G.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Peth\u00f6-Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E. A.","family":"Borm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-3495","authenticated-orcid":true,"given":"Petra","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes W. J.","family":"Bijlsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris P. J. G.","family":"Lafeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"pone.0241189.ref001","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","journal-title":"Lancet"},{"key":"pone.0241189.ref002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/qjmed\/hcp165","article-title":"Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies","volume":"103","author":"YW Song","year":"2010","journal-title":"Q J Med"},{"key":"pone.0241189.ref003","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"S Rantapaa-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum"},{"key":"pone.0241189.ref004","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-006-0275-5","article-title":"Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA","volume":"26","author":"S Agrawal","year":"2007","journal-title":"Clin Rheumatol"},{"key":"pone.0241189.ref005","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/ard.2004.033571","article-title":"Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression","volume":"64","author":"J Ronnelid","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"pone.0241189.ref006","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00296-015-3271-8","article-title":"Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis","volume":"35","author":"W Katchamart","year":"2015","journal-title":"Rheumatol Int"},{"key":"pone.0241189.ref007","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s13317-010-0013-5","article-title":"Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab","volume":"1","author":"M Fabris","year":"2010","journal-title":"Auto Immun Highlights"},{"key":"pone.0241189.ref008","doi-asserted-by":"crossref","first-page":"e40362","DOI":"10.1371\/journal.pone.0040362","article-title":"Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis","volume":"7","author":"G Ferraccioli","year":"2012","journal-title":"PLoS One"},{"key":"pone.0241189.ref009","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/annrheumdis-2013-204154","article-title":"Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis","volume":"73","author":"J Shi","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"pone.0241189.ref010","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15537\/smj.2017.9.20841","article-title":"Anti-carbamylated protein antibodies in rheumatoid arthritis patients and their association with rheumatoid factor","volume":"38","author":"MA Othman","year":"2017","journal-title":"Saudi Med J"},{"key":"pone.0241189.ref011","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-018-1520-4","article-title":"Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes","volume":"20","author":"EC De Moel","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"pone.0241189.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"JA Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"pone.0241189.ref013","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"pone.0241189.ref014","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.1002\/art.22943","article-title":"Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients","volume":"56","author":"D Aletaha","year":"2007","journal-title":"Arthritis Rheum"},{"key":"pone.0241189.ref015","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3899\/jrheum.090776","article-title":"Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later","volume":"37","author":"Y Ichikawa","year":"2010","journal-title":"J Rheumatol"},{"key":"pone.0241189.ref016","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.3899\/jrheum.131238","article-title":"When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET)","volume":"41","author":"MR Dougados","year":"2014","journal-title":"J Rheumatol"},{"key":"pone.0241189.ref017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"pone.0241189.ref018","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"D Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"pone.0241189.ref019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial","volume":"388","author":"JWJ Bijlsma","year":"2016","journal-title":"Lancet"},{"key":"pone.0241189.ref020","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jaci.2017.10.003","article-title":"Biomarkers in connective tissue diseases","volume":"140","author":"NR Jog","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"pone.0241189.ref021","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/nrrheum.2017.200","article-title":"The RA-MAP Consortium: a working model for academia\u2013industry collaboration","volume":"14","author":"AP Cope","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0241189.ref022","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-016-1135-6","article-title":"Sequential high-content profiling of the IgG-autoantibody repertoire reveals novel antigens in rheumatoid arthritis","volume":"18","author":"S Vordenb\u00e4umen","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"pone.0241189.ref023","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41397-019-0139-4","article-title":"Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients","volume":"20","author":"SF Ling","journal-title":"Pharmacogenomics J"},{"key":"pone.0241189.ref024","doi-asserted-by":"crossref","first-page":"978202","DOI":"10.1155\/2013\/978202","article-title":"Highlights on novel technologies for the detection of antibodies to Ro60, Ro52, and SS-B","volume":"2013","author":"M Infantino","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"pone.0241189.ref025","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0001-2998(78)80014-2","article-title":"Basic principles of ROC analysis","volume":"8","author":"CE Metz","year":"1978","journal-title":"Semin Nucl Med"},{"key":"pone.0241189.ref026","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing areas under two or more correlated receiver operating characteristics curves: a nonparametric approach","volume":"44","author":"ER Delong","year":"1988","journal-title":"Biometrics"},{"key":"pone.0241189.ref027","first-page":"136","article-title":"Anti-cytokine autoantibodies in autoimmune diseases","volume":"1","author":"G Cappellano","year":"2012","journal-title":"Am J Clin Exp Immunol"},{"key":"pone.0241189.ref028","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41423-018-0170-4","article-title":"Methyltransferase Dot1l preferentially promotes innate IL-6 and IFN-\u03b2 production by mediating H3K79me2\/3 methylation in macrophages","volume":"17","author":"X Chen","journal-title":"Cell Mol Immunol 2020"},{"key":"pone.0241189.ref029","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10067-017-3941-x","article-title":"Increased DOT1L in synovial biopsies of patients with OA and RA","volume":"37","author":"D He","year":"2018","journal-title":"Clin Rheumatol"},{"key":"pone.0241189.ref030","doi-asserted-by":"crossref","first-page":"e17672","DOI":"10.7554\/eLife.17672","article-title":"An alternative splicing program promotes adipose tissue thermogenesis","volume":"5","author":"S Vernia","year":"2016","journal-title":"ELife"},{"key":"pone.0241189.ref031","doi-asserted-by":"crossref","first-page":"8479","DOI":"10.1038\/ncomms9479","article-title":"The alternative splicing factor Nova2 regulates vascular development and lumen formation","volume":"6","author":"C Giampietro","year":"2015","journal-title":"Nat Commun"},{"key":"pone.0241189.ref032","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2249.2005.02760.x","article-title":"Alpha tropomyosin as a self-antigen in patients with Beh\u00e7et\u2019s disease","volume":"140","author":"SP Mahesh","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"pone.0241189.ref033","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/jaut.1996.0107","article-title":"Antibodies in the sera of acute rheumatic fever patients bind to human cardiac tropomyosin","volume":"10","author":"AK Khanna","year":"1997","journal-title":"J Autoimmun"},{"key":"pone.0241189.ref034","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1091\/mbc.9.10.2963","article-title":"The cytoplasmic zinc finger protein ZPR1 accumulates in the nucleolus of proliferating cells","volume":"9","author":"Z Galcheva-Gargova","year":"1998","journal-title":"Mol Biol Cell"},{"key":"pone.0241189.ref035","doi-asserted-by":"crossref","first-page":"R201","DOI":"10.1186\/ar4039","article-title":"Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides","volume":"14","author":"M Hansson","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"pone.0241189.ref036","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.41089","article-title":"Comprehensive profiling of the rheumatoid arthritis antibody repertoire","volume":"72","author":"KC Lo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"pone.0241189.ref037","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12016-007-8029-y","article-title":"Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis","volume":"34","author":"WJ Van Venrooij","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"pone.0241189.ref038","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.aca.2015.02.012","article-title":"A tutorial review: metabolomics and partial least squares-discriminant analysis\u2014a marriage of convenience or a shotgun wedding","volume":"879","author":"PS Gromski","year":"2015","journal-title":"Anal Chim Acta"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T14:32:15Z","timestamp":1607610735000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0241189"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":38,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0241189","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,10]]}}}